Rhythm Pharmaceuticals (RYTM) announced topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 ...

SentinelOne (NYSE: S) has established itself as a leader in endpoint security, safeguarding network-connected devices through ...

Until now, it has been difficult for security programs to determine whether a user has granted permissions to problematic ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Mastering endpoint security requires a combination of advanced tools, strategic integration, and a focus on user experience.

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Traditional EDR reacts to threats as they occur, but PEP takes a proactive stance. By leveraging techniques like Preemptive ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...